Protein Degradation Therapy Global Market Report 2026

Protein degradation therapy is a therapeutic approach that focuses on the selective degradation of specific proteins within cells. This method involves using small molecules, peptides, or other agents to promote the destruction of proteins that are dysfunctional or contribute to disease. The aim is to reduce or eliminate harmful proteins associated with various conditions, such as cancer, neurodegenerative diseases, and autoimmune disorders.

Key therapies in protein degradation include bavdegalutamide (ARV-110), vepdegestrant (ARV-471), and others. Bavdegalutamide, also known as ARV-110, is a novel therapy developed to target and degrade androgen receptors in prostate cancer cells. This therapy is used in the treatment of oncology, neurodegenerative diseases, infectious diseases, and other conditions by various end-users, including pharmaceutical companies, biotechnology companies, and academic and research institutes.

Tariffs are influencing the protein degradation therapy market by increasing costs of imported research reagents, laboratory equipment, specialized chemical compounds, and bioprocessing tools used in drug discovery and clinical development. Biotechnology hubs in North America and Europe are most affected due to reliance on imported research materials, while Asia-Pacific faces cost pressure on compound synthesis and testing. These tariffs are raising R&D expenditures and extending development timelines. However, they are also encouraging localized research infrastructure, domestic reagent production, and regional partnerships in advanced therapeutic development.

The protein degradation therapy market research report is one of a series of new reports from The Business Research Company that provides protein degradation therapy market statistics, including protein degradation therapy industry global market size, regional shares, competitors with a protein degradation therapy market share, detailed protein degradation therapy market segments, market trends and opportunities, and any further data you may need to thrive in the protein degradation therapy industry. This protein degradation therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The protein degradation therapy market size has grown strongly in recent years. It will grow from $1.25 billion in 2025 to $1.35 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to advancements in molecular biology research, expansion of targeted cancer therapies, increased understanding of protein dysfunction in diseases, early-stage clinical successes, growing venture capital funding in biotech.

The protein degradation therapy market size is expected to see strong growth in the next few years. It will grow to $1.83 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing demand for novel cancer therapies, rising investments in precision oncology, expansion of protein degradation platforms, growing clinical trial activity, increasing regulatory support for innovative therapeutics. Major trends in the forecast period include increasing development of targeted protein degraders, rising focus on oncology applications, growing investment in protac-based therapies, expansion of clinical pipeline candidates, enhanced collaboration between pharma and biotech firms.

The increasing burden of cancer is expected to drive the growth of the protein degradation therapy market in the future. Cancer encompasses a variety of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. The rising cancer rates are largely due to factors such as an aging population, lifestyle choices like smoking, poor diet, lack of physical activity, and increasing obesity rates, all of which have heightened the risk of different cancers. Protein degradation therapy is vital for treating cancer because it targets and eliminates specific proteins that promote cancer growth and survival, potentially overcoming resistance to conventional treatments. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, predicted that over 35 million new cancer cases are expected by 2050, marking a 77% increase from the estimated 20 million cases in 2022. Furthermore, high human development index (HDI) countries are forecasted to experience the largest rise in absolute numbers, with an additional 4.8 million new cases in 2050 compared to 2022 estimates. Therefore, the growing cancer burden is fueling the expansion of the protein degradation therapy market.

Leading companies in the protein degradation therapy market are forming strategic partnerships to develop innovative therapies, leverage complementary expertise, share resources, and accelerate the discovery and development of new drug candidates targeting disease-causing proteins. These partnerships enable companies to use each other's strengths and resources to gain mutual benefits and achieve shared success. For example, in February 2024, Arvinas, a U.S.-based biotechnology company, launched its first oral PROTAC degrader (ARV-102), designed to cross the blood-brain barrier and target LRRK2 for neurodegenerative disease applications. The ARV-102 molecule offers oral bioavailability, brain penetration, and high specificity for LRRK2. This innovation strengthens the company's pipeline by targeting previously undruggable targets, although challenges remain around long-term safety, manufacturing complexity, and optimizing pharmacokinetics due to the larger molecular structure.

In June 2024, Genexine, a South Korea-based biopharmaceutical company, merged with EPD Biotherapeutics for an undisclosed amount. This merger enabled Genexine to acquire key talent and cutting-edge technology, positioning it to lead the global market. Additionally, the integration of EPD Bio's bioPROTAC technology with Genexine's clinical and CMC development capabilities is expected to accelerate the development of groundbreaking new drugs. EPD Biotherapeutics is a South Korea-based developer of the protein degradation platform known as EPDeg.

Major companies operating in the protein degradation therapy market are Relay Therapeutics, Arvinas Holding Company LLC, Kymera Therapeutics, Nurix Therapeutics, Vividion Therapeutics, Mission Therapeutics Ltd., C4 Therapeutics Inc., Cullgen Inc., Frontier Medicines, Foghorn Therapeutics, Aileron Therapeutics, Ribometrix Inc., Nimbus Therapeutics, Jnana Therapeutics, KSQ Therapeutics, Stoke Therapeutics, Flare Therapeutics, Accent Therapeutics, Monte Rosa Therapeutics, Lycia Therapeutics, Dialectic Therapeutics, Amphista Therapeutics, Biotheryx Inc., Cedilla Therapeutics, Dewpoint Therapeutics Inc

North America was the largest region in the protein degradation therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the protein degradation therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the protein degradation therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The protein degradation therapy market consists of revenues earned by entities by providing services such as drug discovery and development, target validation, preclinical and clinical testing and targeted protein degradation screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The protein degradation therapy market also includes sales of degraders, E3 ligase ligands, degron tags, biochemical assay kits and cellular assay kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Protein Degradation Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses protein degradation therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for protein degradation therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The protein degradation therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Bavdegalutamide (ARV - 110); Vepdegestrant (ARV - 471)
• 2) By Application: Oncology; Neurodegenerative Diseases; Infectious Diseases; Other Applications
• 3) By End-User: Pharmaceutical Companies; Biotechnology Companies; Academic And Research Institutes
• Subsegments:
• 1) By Bavdegalutamide (ARV-110): Androgen Receptor Degraders; Prostate Cancer Therapy
• 2) By Vepdegestrant (ARV-471): Estrogen Receptor Degraders; Breast Cancer Therapy
• Companies Mentioned: Relay Therapeutics; Arvinas Holding Company LLC; Kymera Therapeutics; Nurix Therapeutics; Vividion Therapeutics; Mission Therapeutics Ltd.; C4 Therapeutics Inc.; Cullgen Inc.; Frontier Medicines; Foghorn Therapeutics; Aileron Therapeutics; Ribometrix Inc.; Nimbus Therapeutics; Jnana Therapeutics; KSQ Therapeutics; Stoke Therapeutics; Flare Therapeutics; Accent Therapeutics; Monte Rosa Therapeutics; Lycia Therapeutics; Dialectic Therapeutics; Amphista Therapeutics; Biotheryx Inc.; Cedilla Therapeutics; Dewpoint Therapeutics Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.